Clinical relevance of antifungal resistance (Q41676916)

6 October 2017

1 reference

title

Clinical relevance of antifungal resistance (English)

1 reference

6 October 2017

Espinel-Ingroff A

1

1 reference

6 October 2017

publication date

1 December 1997

1 reference

Infectious Disease Clinics of North America

6 October 2017

published in

1 reference

6 October 2017

volume

11

1 reference

6 October 2017

issue

4

1 reference

6 October 2017

page(s)

929-944

1 reference

The Emerging Role of Fusarium Infections in Patients with Cancer

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Correlation between in vitro and in vivo activity of antifungal agents against Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole-resistant candidosis in an HIV cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole-resistant Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Reversible fluconazole resistance in Candida albicans: a potential in vitro model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Disseminated Candidiasis Due to Amphotericin B-Resistant Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Incidence of polyene-resistant yeasts recovered from clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole failure in the treatment of invasive mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Rising Incidence of Candida parapsilosis Fungemia in Patients with Hematologic Malignancies: Clinical Aspects, Predisposing Factors, and Differential Pathogenicity of the Causative Strains

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Risk factors for fungemia in children infected with human immunodeficiency virus: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Resistance of Candida albicans biofilms to antifungal agents in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole-resistant Candida in AIDS patients. Report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole-resistant Candida albicans in an immunocompetent child.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

ABC Transporters: From Microorganisms to Man

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Resistance of Candida albicans to azole antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase, and inhibition by azole antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Origin of differences in susceptibility of Candida krusei to azole antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a Human

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Amphotericin B-resistant yeast infection in severely immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Editorial response: management of cryptococcal meningitis--have we answered all the questions?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Correlation of in Vitro Susceptibility Test Results with in Vivo Response: Flucytosine Therapy in a Systemic Candidiasis Model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Characterization of an azole-resistant Candida glabrata isolate

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Molecular mechanisms of drug resistance in fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

In vitro interaction between amphotericin B and azoles in Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Inhibition and interaction of cytochrome P450 ofCandida kruseiwith azole antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Fluconazole resistance in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Scedosporium inflatum: clinical spectrum of a newly recognized pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Candida tropicalis: A Major Pathogen in Immunocompromised Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970398-6

7 January 2021

10.1016/S0891-5520(05)70398-6

Identifiers

DOI

1 reference

6 October 2017

1 reference